Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme

Cytokine and Growth Factor Reviews

Volumn 21, Issue 2-3, 2010, Pages 197-203

  Goetz, Christian ^a   Gromeier, Matthias ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Central nervous system; Glioblastoma multiforme; PVS RIPO

Indexed keywords

INITIATION FACTOR 3; INITIATION FACTOR 4E; ONCOLYTIC POLIOMYELITIS VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; GENETIC MANIPULATION; GENETIC STABILITY; GLIOBLASTOMA; HUMAN; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVIEW; TRANSLATION INITIATION; TRANSLATION REGULATION; VIRUS ENTRY; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENETICS; PATHOLOGY; PHYSIOLOGY; POLIOMYELITIS VIRUS; PROCEDURES; PROTEIN SYNTHESIS; RHINOVIRUS; XENOGRAFT;

ANIMALIA; HUMAN POLIOVIRUS 1; HUMAN RHINOVIRUS SP.; POLIOVIRUS;

ANIMALS; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENOME, VIRAL; GLIOBLASTOMA; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; POLIOVIRUS; PROTEIN BIOSYNTHESIS; RHINOVIRUS; TRANSPLANTATION, HETEROLOGOUS;

EID: 77953508940     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.02.005     Document Type: Review

References (70)

1. Sinkovics J.G., Horvath J.C. Virus therapy of human cancers. Melanoma Res 2003, 13:431-432.
2. Gromeier M. Viruses for treating cancer. ASM News 2002, 68:438-445.
3. Coffey M.C., Strong J.E., Forsyth P.A., Lee P.W. Reovirus therapy of tumors with activated Ras pathway. Science 1998, 282:1332-1334.
4. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000, 6:821-825.
5. Wang G., Barrett J.W., Stanford M., Werden S.J., Johnston J.B., Gao X., et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA 2006, 103:4640-4645.
6. Balachandran S., Barber G.N. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 2004, 5:51-65.
7. McFadden G. Poxvirus tropism. Nat Rev Microbiol 2005, 3:201-213.
8. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376.
9. Martuza R.L., Malick A., Markert J.M., Ruffner K.L., Coen D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252:854-856.
10. Gromeier M., Lachmann S., Rosenfeld M.R., Gutin P.H., Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 2000, 97:6803-6808.
11. Andreansky S.S., He B., Gillespie G.Y., Soroceanu L., Markert J.M., Chou J., et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 1996, 93:11313-11318.
12. Kambara H., Okano H., Chiocca E.A., Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005, 65:2832-2839.
13. Campbell S.A., Mulvey M., Mohr I., Gromeier M. Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements. J Virol 2007, 81:791-799.
14. Chou J., Kern E.R., Whitley R.J., Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990, 250:1262-1266.
15. Chou J., Roizman B. Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc Natl Acad Sci USA 1994, 91:5247-5251.
16. He B., Gross M., Roizman M. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997, 94:843-848.
17. Hunter W.D., Martuza R.L., Feigenbaum F., Todo T., Mineta T., Yazaki T., et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999, 73:6319-6326.
18. Taneja S., MacGregor J., Markus S., Ha S., Mohr I. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001, 98:8804-8808.
19. Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006, 439:344-348.
20. Pfeiffer J.K., Kirkegaard K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog 2005, 1:e11.
21. Mendelsohn C.L., Wimmer E., Racaniello V.R. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 1989, 56:855-865.
22. Takai Y., Miyoshi J., Ikeda W., Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol 2008, 9:603-615.
23. Geraghty R.J., Krummenacher C., Cohen G.H., Eisenberg R.J., Spear P.G. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998, 280:1618-1620.
24. Takahashi K., Nakanishi H., Miyahara M., Mandai K., Satoh K., Satoh A., et al. Nectin/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein. J Cell Biol 1999, 145:539-549.
25. Suzuki K., Hu D., Bustos T., Zlotogara J., Richieri-Costa A., Helms J.A., et al. Mutations of PVRL1, encoding a cell-cell adhesion molecule/herpesvirus receptor, in cleft lip/palate-ectodermal dysplasia. Nat Genet 2000, 25:427-430.
26. Aoki J., Koike S., Asou H., Ise I., Suwa H., Tanaka T., et al. Mouse homolog of poliovirus receptor-related gene 2 product, mPRR2, mediates homophilic cell aggregation. Exp Cell Res 1997, 235:374-384.
27. Reymond N., Borg J.P., Lecocq E., Adelaide J., Campadelli-Fiume G., Dubreuil P., et al. Human nectin3/PRR3: a novel member of the PVR/PRR/nectin family that interacts with afadin. Gene 2000, 255:347-355.
28. Reymond N., Fabre S., Lecocq E., Adelaide J., Dubreuil P., Lopez M. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem 2001, 276:43205-43215.
29. Kakunaga S., Ikeda W., Itoh S., Deguchi-Tawarada M., Ohtsuka T., Mizoguchi A., et al. Nectin-like molecule-1/TSLL1/SynCAM3: a neural tissue-specific immunoglobulin-like cell-cell adhesion molecule localizing at non-junctional contact sites of presynaptic nerve terminals, axons and glia cell processes. J Cell Sci 2005, 118:1267-1277.
30. Shingai T., Ikeda W., Kakunaga S., Morimoto K., Takekuni K., Itoh S., et al. Implications of nectin-like molecule 2/IGSF4/RA175SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and transmembrane protein localization in epithelial cells. J Biol Chem 2003, 278:35421-35427.
31. Pellissier F., Gerber A., Bauer C., Ballivet M., Ossipow V. The adhesion molecule Necl-3/SynCAM-2 localizes to myelinated axons, binds to oligodendrocytes and promotes cell adhesion. BMC Neurosci 2007, 8:90.
32. Maurel P., Einheber S., Galinska J., Thaker P., Lam I., Rubin M.B., et al. Nectin-like proteins mediate axon Schwann cell interactions along the internode and are essential for myelination. J Cell Biol 2007, 178:861-874.
33. Masson D., Jarry A., Baury B., Blanchardie P., Laboisse C., Lustenberger P., et al. Overexpression of the CD155 gene in human colorectal carcinoma. Gut 2001, 49:236-240.
34. Ochiai H., Moore S.A., Archer G.E., Okamura T., Chewning T.A., Marks J.R., et al. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res 2004, 10:4831-4838.
35. Merrill M.K., Bernhardt G., Sampson J.H., Wikstrand C.J., Bigner D.D., Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neurooncology 2004, 6:208-217.
36. Sloan K.E., Stewart J.K., Treloar A.F., Matthews R.T., Jay D.G. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res 2005, 65:10930-10937.
37. Sloan K.E., Eustace B.K., Stewart J.K., Zehetmeier C., Torella C., Simeone M., et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 2004, 4:73.
38. Solecki D.J., Gromeier M., Mueller S., Bernhardt G., Wimmer E. Expression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog. J Biol Chem 2002, 277:25697-25702.
39. Hirota T., Irie K., Okamoto R., Ikeda W., Takai Y. Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by fibroblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway. Oncogene 2005, 24:2229-2235.
40. Erickson B.M., Thompson N.L., Hixson D.C. Tightly regulated induction of the adhesion molecule necl-5/CD155 during rat liver regeneration and acute liver injury. Hepatology 2006, 43:325-334.
41. Waehler R., Russell S.J., Curiel D.T. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007, 8:573-587.
42. Grandi P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D.T., et al. HSV-1 virions engineered for specific binding to cell surface receptors. Mol Ther 2004, 9:419-427.
43. Gromeier M., Solecki D., Patel D.D., Wimmer E. Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis. Virology 2000, 273:248-257.
44. Gromeier M., Alexander L., Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci USA 1996, 93:2370-2375.
45. Nomoto A., Lee Y.F. Wimmer E. The 5' end of poliovirus mRNA is not capped with m7G(5')ppp(5')Np. Proc Natl Acad Sci USA 1976, 73:375-380.
46. Kaiser C., Dobrikova E.Y., Bradrick S.S., Shveygert M., Herbert J.T., Gromeier M. Activation of cap-independent translation by variant eukaryotic initiation factor 4G in vivo. RNA 2008, 14:2170-2182.
47. de Breyne S., Yu Y., Unbehaun A., Pestova T.V., Hellen C.U. Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites. Proc Natl Acad Sci USA 2009, 106:9197-9202.
48. Jang S.K., Krausslich H.G., Nicklin M.J., Duke G.M., Palmenberg A.C., Wimmer E. A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J Virol 1988, 62:2636-2643.
49. Pelletier J., Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 1988, 334:320-325.
50. Gromeier M., Bossert B., Arita M., Nomoto A., Wimmer E. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J Virol 1999, 73:958-964.
51. Campbell S.A., Lin J., Dobrikova E.Y., Gromeier M. Genetic determinants of cell typespecific poliovirus propagation in HEK 293 cells. J Virol 2005, 79:6281-6290.
52. Shaw G., Morse S., Ararat M., Graham F.L. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 2002, 16:869-871.
53. Merrill M.K., Gromeier M. The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. J Virol 2006, 80:6936-6942.
54. Merrill M.K., Dobrikova E.Y., Gromeier M. Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76. J Virol 2006, 80:3147-3156.
55. Florez de Sessions P., Dobrikova E., Gromeier M. Genetic adaptation to untranslated region-mediated enterovirus growth deficits by mutations in the nonstructural proteins 3AB and 3CD. J Virol 2007, 81:8396-8405.
56. Dobrikova E., Florez P., Bradrick S., Gromeier M. Activity of a type 1 picornavirus internal ribosomal entry site is determined by sequences within the 3' nontranslated region. Proc Natl Acad Sci USA 2003, 100:15125-15130.
57. Dobrikova E.Y., Broadt T., Poiley-Nelson J., Yang X., Soman G., Giardina S., et al. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol Ther 2008, 16:1865-1872.
58. Yang X., Chen E., Jiang H., Muszynski K., Harris R.D., Giardina S.L., et al. Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. J Virol Methods 2009, 155:44-54.
59. Holland E.C., Celestino J., Dai C., Schaefer L., Sawaya R.E., Fuller G.N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000, 25:55-57.
60. Rajasekhar V.K., Viale A., Socci N.D., Wiedmann M., Hu X., Holand E.C., et al. Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003, 12:889-901.
61. Pause A., Belsham G.J., Gingras A.C., Donze O., Lin T.A., Lawrence J.C., et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature 1994, 371:762-767.
62. Beretta L., Gingras A.C., Svitkin Y.V., Hall M.N., Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996, 15:658-664.
63. Waskiewicz A.J., Flynn A., Proud C.G., Cooper J.A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997, 16:1909-1920.
64. Fukunaga R., Hunter T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J 1997, 16:1921-1933.
65. Raught B., Gingras A.C., Gygi Sp, Imataka H., Morino S., Gradi A., et al. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J 2000, 19:434-444.
66. Lamphear B.J., Kirchweger R., Skern T., Rhoads R.E. Mapping of functional domains in eukaryotic protein synthesis initiation factor 4G (eIF4G) with picornaviral proteases. Implications for cap-dependent and cap-independent translational initiation. J Biol Chem 1995, 270:21975-21983.
67. Pyronnet S., Imataka H., Gingras A.C., Fukunaga R., Hunter T., Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 1999, 18:270-279.
68. Scheper G.C., Proud C.G. Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation?. Eur J Biochem 2002, 269:5350-5359.
69. Knauf U., Tschopp C., Gram H. Negative regulation of protein translation by mitogenactivated protein kinase-interacting kinases 1 and 2. Mol Cell Biol 2001, 21:5500-5511.
70. Svitkin Y.V., Herdy B., Costa-Mattioli M., Gingras A.C., Raught B., Sonenberg H. Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol Cell Biol 2005, 25:10556-10565.